Department of General, Visceral, Cancer and Transplantation Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Else Kröner Forschungskolleg Cologne "Clonal Evolution in Cancer", Faculty of Medicine and University Hospital, Weyertal 115B, Cologne, 50937, Germany.
J Cancer Res Clin Oncol. 2022 May;148(5):1223-1234. doi: 10.1007/s00432-021-03720-5. Epub 2021 Jul 5.
Patients with locally advanced esophageal or gastroesophageal adenocarcinoma benefit from multimodal therapy concepts including neoadjuvant chemoradiation (nCRT), respectively, perioperative chemotherapy (pCT). However, it remains unclear which treatment is superior concerning postoperative morbidity.
In this study, we compared the postsurgical survival (30-day/90-day/1-year mortality) (primary endpoint), treatment response, and surgical complications (secondary endpoints) of patients who either received nCRT (CROSS protocol) or pCT (FLOT protocol) due to esophageal/gastroesophageal adenocarcinoma. Between January 2013 and December 2017, 873 patients underwent Ivor Lewis esophagectomy in our high-volume center. 339 patients received nCRT and 97 underwent pCT. After 1:1 propensity score matching (matching criteria: sex, age, BMI, ASA score, and Charlson score), 97 patients per subgroup were included for analysis.
After matching, tumor response (ypT/ypN) did not differ significantly between nCRT and pCT (p = 0.118, respectively, p = 0.174). Residual nodal metastasis occurred more often after pCT (p = 0.001). Postsurgical mortality was comparable within both groups. No patient died within 30 or 90 days after surgery while the 1-year survival rate was 72.2% for nCRT and 68.0% for pCT (p = 0.47). Only grade 3a complications according to Clavien-Dindo were increased after pCT (p = 0.04). There was a trend towards a higher rate of pylorospasm within the pCT group (nCRT: 23.7% versus pCT: 37.1%) (p = 0.061). Multivariate analysis identified pCT, younger age, and Charlson score as independent variables for pylorospasm.
Both nCRT and pCT are safe and efficient within the multimodal treatment of esophageal/gastroesophageal adenocarcinoma. We did not observe differences in postoperative morbidity. However, functional aspects such as gastric emptying might be more frequent after pCT.
局部晚期食管或胃食管腺癌患者受益于新辅助放化疗(nCRT)和围手术期化疗(pCT)等多模式治疗方案。然而,术后发病率方面哪种治疗方案更具优势仍不明确。
本研究比较了因食管/胃食管腺癌分别接受 nCRT(CROSS 方案)或 pCT(FLOT 方案)治疗的患者的术后生存(30 天/90 天/1 年死亡率)(主要终点)、治疗反应和手术并发症(次要终点)。2013 年 1 月至 2017 年 12 月,我们的大容量中心有 873 例患者接受 Ivor Lewis 食管切除术。339 例患者接受 nCRT,97 例患者接受 pCT。经 1:1 倾向评分匹配(匹配标准:性别、年龄、BMI、ASA 评分和 Charlson 评分)后,每组纳入 97 例患者进行分析。
匹配后,nCRT 和 pCT 组的肿瘤反应(ypT/ypN)无显著差异(p=0.118,p=0.174)。pCT 后残留淋巴结转移更为常见(p=0.001)。两组术后死亡率相当。无患者术后 30 天或 90 天内死亡,nCRT 组 1 年生存率为 72.2%,pCT 组为 68.0%(p=0.47)。只有根据 Clavien-Dindo 分级的 3a 级并发症在 pCT 后增加(p=0.04)。pCT 组胃出口梗阻发生率较高(nCRT:23.7% vs. pCT:37.1%)(p=0.061)。多变量分析确定 pCT、年龄较小和 Charlson 评分是胃出口梗阻的独立变量。
nCRT 和 pCT 均为食管/胃食管腺癌多模式治疗的安全有效方法。我们未观察到术后发病率方面的差异。然而,pCT 后胃排空等功能方面可能更为常见。